As further sharp declines are expected for Humira, AbbVie has strategically pivoted to alternative immunology products to bolster its revenue streams. As such, two drugs, Skyrizi (risankizumab) and Rinvoq (upadacitinib), are emerging as key replacements. These products are forecast to collectively generate over $32 billion by 2030, enabling AbbVie to financially rebound and continue its position as a leading immunology player, says GlobalData.